EffRx Pharmaceuticals SA announced that it has signed an exclusive licensing and distribution agreement with Radius Health Inc. for Binosto®? for the United States. BINOSTO®?

is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO®®? provides an important once-weekly treatment option, particularly for patients with osteoporosis who may not be able to take alendronate tablets.

Radius is a major player in the U.S. bone market and currently markets TYMLOS®? for the treatment of osteop orosis in the U.S. BINOSTO®?? expands Radius' presence in the treatment of bone health with a second product for the approximately 10 million people in the U.S. living with osteoporosis.

Under the terms of the agreement, EffRx will grant Radius an exclusive, royalty bearing license to BINOSTO® in the U.S. and will also supply product to Radius.